Marburg virus kills 15 in Rwanda's first-ever confirmed outbreak, with 66 cases concentrated among healthcare workers at Kigali hospitals
Rwanda confirmed its first Marburg virus disease outbreak on September 27, 2024, with 66 confirmed cases and 15 deaths by the time WHO declared the outbreak over on December 20, 2024; 80% of cases were healthcare workers at King Faisal Hospital and Rwanda Military Hospital in Kigali, where the index case had worked in an intensive care unit; WHO and Rwanda's rapid containment set a new benchmark for haemorrhagic fever outbreak response in Africa
리스트에 추가
아직 리스트가 없습니다.
Summary
Rwanda declared its first Marburg virus disease outbreak on September 27, 2024, after laboratory tests confirmed that deaths among healthcare workers at Kigali's King Faisal Hospital were caused by Marburg virus, a rare and highly lethal haemorrhagic fever in the same family as Ebola. The outbreak reached a total of 66 confirmed cases and 15 deaths (case fatality rate approximately 23%) before WHO declared it over on December 20, 2024. Approximately 80% of confirmed cases were healthcare workers, a pattern consistent with nosocomial amplification from an unrecognised initial case. Rwandan authorities, WHO, and Africa CDC deployed contact tracers to identify more than 4,000 contacts, and an experimental Sabin Institute monovalent Marburg vaccine was administered to exposed healthcare workers under compassionate use. Egyptian fruit bats at a cave site near Kigali were identified as the probable reservoir.
The split
Rwanda's government and WHO agreed to publish real-time case data, a transparency that stood in contrast to several prior African haemorrhagic fever outbreaks and was credited by WHO as enabling faster international deployment of diagnostic and response teams. Rwanda's health minister attributed the relatively low case fatality rate (23%, compared to the 50-88% range in historical Marburg outbreaks) in part to early intensive care access for confirmed cases. Global health researchers used the outbreak to advocate for accelerated regulatory approval of Marburg vaccines, noting that two candidates (Sabin Institute and IAVI) had shown promising Phase I safety data but lacked the efficacy data needed for full licensure. The outbreak also triggered a debate about bat cave tourism and bushmeat markets as outbreak ignition vectors.
By the numbers
- 66: confirmed Marburg cases in Rwanda's 2024 outbreak
- 15: deaths (case fatality rate ~23%)
- ~80%: share of confirmed cases who were healthcare workers
- 4,000+: contacts traced during the response
- December 20, 2024: date WHO declared the outbreak over
- 83 days: duration of the active outbreak (September 27 to December 20, 2024)
- 2: candidate Marburg vaccines in Phase I/II trials (Sabin, IAVI) at time of outbreak
Why it matters
Rwanda's 2024 Marburg outbreak was only the third confirmed outbreak in Africa in the 21st century and the first in a country with a modern hospital system and strong public health infrastructure. The Rwanda response is now studied as a model for nosocomial haemorrhagic fever containment: rapid identification, ring vaccination with an experimental product, and aggressive contact tracing. The Marburg virus remains on WHO's priority list of pathogens with pandemic potential, and the Rwanda event renewed pressure for emergency licensing pathways for Marburg vaccines before the next outbreak occurs in a less-equipped country.
What to watch
- Regulatory timeline for full approval of the Sabin Institute and IAVI Marburg vaccine candidates
- Whether Egypt or Tanzania, where Egyptian fruit bat colonies are large, report spillover events
- Post-outbreak longitudinal studies of surviving Rwandan healthcare workers for persistence of Marburg antibodies and long-term sequelae
- WHO's updated Marburg preparedness guidance and stockpiling recommendations following the 2024 Rwanda response review